Jie Wang
Qiqihar University(CN)Nanjing University of Chinese Medicine(CN)Shanghai Jiao Tong University(CN)Chinese Academy of Sciences(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking University(CN)Sichuan University(CN)Inner Mongolia University(CN)Peking Union Medical College Hospital(CN)Xinzhou Teachers University(CN)Zhengzhou University(CN)Soochow University(CN)Nanjing University of Posts and Telecommunications(CN)Affiliated Hospital of Southwest Medical University(CN)North West Agriculture and Forestry University(CN)National Cancer Center(US)Wuhan Institute of Physics and Mathematics(CN)Zhengzhou Children's Hospital(CN)International Peace Maternity & Child Health Hospital(CN)Peking University People's Hospital(CN)Affiliated Hospital of Youjiang Medical University for Nationalities(CN)Cancer Hospital of Chinese Academy of Medical Sciences(CN)Peking University Third Hospital(CN)Henan Cancer Hospital(CN)Seventh People's Hospital of Shanghai(CN)CNC Technology (Czechia)(CZ)Molecular Oncology (United States)(US)First Affiliated Hospital of Soochow University(CN)First Affiliated Hospital of Zhengzhou University(CN)State Key Laboratory of Molecular OncologyTsinghua University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study(2011)4,075 cited
- → Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel(2019)492 cited
- → Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial(2015)405 cited
- → Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC(2020)401 cited
- → Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer(2021)387 cited